Key result
Angiotensin-receptor blockers (ARBs) are not better than angiotensin-converting-enzyme (ACE) inhibitors at reducing fatal and nonfatal cardiovascular events.
Why the study?
Do ARBs reduce fatal and nonfatal cardiovascular events better than ACE inhibitors in patients with cardiovascular disease?
Do ARBs reduce fatal and nonfatal cardiovascular events better than ACE inhibitors in patients with cardiovascular disease?
Answers are grounded in this paper and cite their sources.
This editorial highlights that ARBs do not provide superior cardiovascular event reduction compared to ACE inhibitors, reinforcing the established role of ACE inhibitors.
The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET, NCT00153101), reported by Yusuf et al.1 in this issue of the Journal, has important lessons for clinical practice and also illustrates the complexities of designing, conducting, analyzing, and interpreting trials comparing new treatments that act in a manner similar to that of established therapies. As the fourth and largest comparative trial, the ONTARGET study confirms, beyond doubt, that angiotensin-receptor blockers (ARBs) are not better than angiotensin-converting–enzyme (ACE) inhibitors at reducing fatal and nonfatal cardiovascular events. Of course, physicians and patients might still choose to use an ARB . . .
No takes yet. Share an insight, caveat, or question.
John J.V. McMurray (2008) conducted an editorial in Cardiovascular Disease. Angiotensin-receptor blockers (ARBs) vs. Angiotensin-converting-enzyme (ACE) inhibitors was evaluated on Fatal and nonfatal cardiovascular events. Angiotensin-receptor blockers (ARBs) are not better than angiotensin-converting-enzyme (ACE) inhibitors at reducing fatal and nonfatal cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: